Breaking News Updates for the Psychedelics Industry | Page 8 of 9

Psychedelics News

Breaking News

9 Mar 2022

Numinus Gets Approval to Research Ayahuasca & San Pedro

Numinus has just received approval from Health Canada to study Ayahuasca and San Pedro....

By Jason Najum

Breaking News, Industry

1 Mar 2022

Calgary-based Med Plant Science Ltd. granted license to research and develop psychedelics in St Vincent and the Grenadines

Calgary-based biotech company, Med Plant Science Ltd, has been awarded a license for medicinal plants containing psychedelic compounds by the St....

By Microdose

Breaking News

21 Feb 2022

Cathie Wood and ARK Increase Support for Psychedelics

ARKG has increased their investment approx 4-fold, buying ATAI an additional 4 times and bringing their total to over 340,000 shares (approx $2 million at current value)....

By Jason Najum

Breaking News, Science

16 Feb 2022

Johns Hopkins Study Shows Psilocybin Effective for a Year

A new study by Johns Hopkins Medicine shows that the antidepressant effects of psilocybin (with psychotherapy) can last at least a year after treatment....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News

10 Feb 2022

Star Investor Cathie Wood Finally Buys Into Psychedelics

ARK Genomic Revolution ETF bought 83,278 shares of atai Life Sciences, its first foray into psychedelics....

By Jason Najum

Breaking News, Industry

9 Feb 2022

Cybin Granted DMT Patent for CYB004

Developing and securing intellectual property is one of the most important tasks of a psychedelic medicine firm....

By Jason Najum

Breaking News, Law & Politics

4 Feb 2022

Breaking News: Health Canada Denies Psilocybin Access

The federal government has just denied dozens of health care professionals seeking psilocybin access and training under section 56 exemption application....

By Jason Najum

Breaking News

25 Jan 2022

Breaking News: FDA Clears MindMed’s Phase 2b LSD Trial

FDA clearance leads to first commercial IND for LSD, enabling MinfdMed to start Phase 2b dose-optimization trial in early 2022...

By Jason Najum

Breaking News

11 Jan 2022

Awakn Announces Positive Results from Phase II Trial of Alcohol Use Disorder

Primary and Secondary Endpoints Achieved, Including 86% Abstinence Over 6 Months Post Treatment and No Serious Adverse Events...

By Microdose

Follow us on social

Latest News

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result